Evaluation of the Safety and Efficacy of a Guided Bone Regeneration Membrane for the Treatment of Femoral Fractures

This study is not yet open for participant recruitment.
Verified September 2012 by RegeneCure, Ltd.
Sponsor:
Information provided by (Responsible Party):
RegeneCure, Ltd.
ClinicalTrials.gov Identifier:
NCT01687530
First received: September 9, 2012
Last updated: September 18, 2012
Last verified: September 2012
  Purpose

Certain types of fractures require surgical intervention that may involve the use of bone grafts or bone graft substitutes. Many of the materials used as bone graft substitutes suffer from disadvantages such as soft tissue invasion of the fracture area, inadequate blood supply, failure to encourage the production of bone and ectopic bone formation.

A guided bone regeneration (GBR) environment may help in solving these clinical concerns. GBR has been widely used in the field of dentistry since the 1980s to provide stable placement for dental implants.

The purpose of this study is to evaluate the safety, performance and initial efficacy of Regenecure's, AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.


Condition Intervention Phase
Proximal (Subtrochanteric)Femoral Fractures
Distal Femoral Fractures
Procedure: AMCA Bone Membrane.
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the Safety Performance and Initial Efficacy of a Guided Bone Regeneration Membrane for the Treatment of Proximal (Subtrochanteric) and Distal Femoral Fractures

Resource links provided by NLM:


Further study details as provided by RegeneCure, Ltd.:

Primary Outcome Measures:
  • Safety will be measured by evaluation of swelling, clinical signs of superficial or deep infection, pain in the operated area [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    To demonstrate the safety of the AMCA Bone membrane when used in the treatment of subtrochanteric and distal femoral fractures.


Secondary Outcome Measures:
  • efficacy will be assessed by radiographic evaluation. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    To evaluate the performance of the AMCA Bone membrane in providing enhanced healing of compromised fractures at risk of non-union.


Estimated Enrollment: 30
Arms Assigned Interventions
Experimental: AMCA bone membrane
AMCA Bone is manufactured from Polyethylene Glycol 400 and Ammonio Methacrylate copolymer type A (Eudragit RL 100) materials.
Procedure: AMCA Bone Membrane.
AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age: 18 to 65
  2. Males Females - non child bearing potential, or females of child-bearing potential who have a negative pregnancy test (hCG urine) within 72 hours of informed consent.
  3. Femoral subtrochanteric fracture and/or fracture of the distal third of the femur
  4. The fracture is classified as one of the following:

    • Closed fracture
    • AO 31 A3, 33b + C1 + C2, and extending to the distal third (see Appendix A for AO fracture classification)
  5. Distal femur fracture will be treated with distal femoral anatomical locking, plate.
  6. Proximal subtrochanteric femoral fracture will be treated with a cephalomedullary nail.

    • Patients must be available for follow-up for a minimum of 12 months.

Exclusion Criteria:

  1. Active systemic or local infection.
  2. History of malignancy, radiotherapy, or chemotherapy for malignancy (except basal cell carcinoma of the skin)
  3. Active autoimmune disease.
  4. Any past or present immunosuppressive treatment.
  5. Open fractures.
  6. Administration of drugs that may interfere with bone metabolism:
  7. Accumulative dose of 150 mg total prednisone or any other gluco-corticosteroid for 7 days or more, within the last 6 months prior to the study;
  8. Calcitonin for 7 days or more within the last 6 months prior to the study;
  9. Bisphosphonates for 30 days or more within the last 12 months prior to the study;
  10. Bone therapeutic doses of fluoride for 30 days or more within the last 12 months prior to the study;
  11. Bone therapeutic doses of vitamin D or vitamin D metabolites for 30 days or more within the last 6 months;
  12. Current treatment with chemotherapeutic agents.
  13. History of metabolic bone disease (primary or secondary).
  14. Chronic renal insufficiency (defined by 50% increase of normal levels).
  15. Administration of marrow suppressive drugs (e.g., vancomycin).
  16. Alcohol abuse
  17. Drug addiction
  18. Smoking (more than 20 cigarettes per day)Bilateral fractures 19 Polytrauma with head injury and patient with periprosthetic fractures.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01687530

Locations
Israel
Hadassah Medical Organization, Orthopedic Surgery Department Not yet recruiting
Jerusalem, Israel
Contact: Amal Khoury, M.D     972-2-6423074        
United Kingdom
Academic Department Of Trauma and Orthipedic Surgery School Of Medicine , Universuty of Leeds Not yet recruiting
Leeds, United Kingdom
Contact: Peter Giannadis     +441133922750        
Sponsors and Collaborators
RegeneCure, Ltd.
Investigators
Study Chair: Peter Giannoudis, Prof. Leeds Hospital
Study Director: Amal Khoury, M.D Hadassah Medical Organization
  More Information

No publications provided

Responsible Party: RegeneCure, Ltd.
ClinicalTrials.gov Identifier: NCT01687530     History of Changes
Other Study ID Numbers: REGO01/12
Study First Received: September 9, 2012
Last Updated: September 18, 2012
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Femoral Fractures
Fractures, Bone
Wounds and Injuries
Leg Injuries
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Hemostatics
Coagulants
Hematologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 22, 2013